statistiche ricercatore

ACCOLLA, ROBERTO

Distribuzione geografica

Continente	#
NA - Nord America	23.949
EU - Europa	16.208
AS - Asia	9.880
SA - Sud America	974
AF - Africa	149
OC - Oceania	25
Continente sconosciuto - Info sul continente non disponibili	13
Totale	51.198

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	23.601
IT - Italia	7.711
SG - Singapore	3.137
UA - Ucraina	2.752
CN - Cina	2.190
VN - Vietnam	1.518
TR - Turchia	1.424
DE - Germania	1.290
SE - Svezia	1.066
HK - Hong Kong	1.060
BR - Brasile	843
FI - Finlandia	747
IE - Irlanda	664
FR - Francia	600
GB - Regno Unito	538
RU - Federazione Russa	484
CA - Canada	208
IN - India	187
MX - Messico	114
PL - Polonia	81
JP - Giappone	78
NL - Olanda	62
AR - Argentina	51
BD - Bangladesh	50
ES - Italia	48
BE - Belgio	47
NG - Nigeria	44
ZA - Sudafrica	44
IQ - Iraq	39
PK - Pakistan	35
LT - Lituania	25
AT - Austria	20
AU - Australia	19
EC - Ecuador	17
KR - Corea	17
VE - Venezuela	16
AE - Emirati Arabi Uniti	15
MA - Marocco	15
CZ - Repubblica Ceca	14
PY - Paraguay	14
SA - Arabia Saudita	14
CH - Svizzera	12
EU - Europa	12
MY - Malesia	12
PH - Filippine	11
JO - Giordania	10
UZ - Uzbekistan	10
CL - Cile	9
CO - Colombia	9
DZ - Algeria	9
ID - Indonesia	9
KE - Kenya	9
EG - Egitto	8
IR - Iran	8
NP - Nepal	8
TN - Tunisia	8
PE - Perù	7
JM - Giamaica	6
BY - Bielorussia	5
LB - Libano	5
NZ - Nuova Zelanda	5
PS - Palestinian Territory	5
TW - Taiwan	5
DK - Danimarca	4
DO - Repubblica Dominicana	4
GE - Georgia	4
IL - Israele	4
RO - Romania	4
RS - Serbia	4
TT - Trinidad e Tobago	4
BG - Bulgaria	3
BH - Bahrain	3
CI - Costa d'Avorio	3
GR - Grecia	3
GY - Guiana	3
HN - Honduras	3
HR - Croazia	3
KH - Cambogia	3
KZ - Kazakistan	3
LU - Lussemburgo	3
MD - Moldavia	3
OM - Oman	3
PA - Panama	3
AL - Albania	2
AZ - Azerbaigian	2
BN - Brunei Darussalam	2
BO - Bolivia	2
ET - Etiopia	2
GA - Gabon	2
HU - Ungheria	2
LV - Lettonia	2
MT - Malta	2
PR - Porto Rico	2
QA - Qatar	2
TG - Togo	2
UY - Uruguay	2
AM - Armenia	1
AO - Angola	1
BA - Bosnia-Erzegovina	1
BB - Barbados	1
Totale	51.178

Salva come PNG Salva come JPEG

Città	#
Milan	5.721
Fairfield	2.139
Jacksonville	2.111
Woodbridge	1.748
Ashburn	1.722
Singapore	1.712
San Jose	1.611
Chandler	1.580
Ann Arbor	1.181
Houston	1.168
Hong Kong	1.041
Seattle	910
Wilmington	910
Dallas	805
Izmir	764
Princeton	716
Dearborn	698
Cambridge	694
Dublin	660
Beijing	587
Nyköping	541
Dong Ket	430
Boardman	427
The Dalles	417
Rome	416
Lauterbourg	315
Chicago	275
San Mateo	242
Como	238
New York	228
Ho Chi Minh City	201
Los Angeles	190
San Diego	165
Ogden	140
Hanoi	137
Orem	137
Helsinki	136
Council Bluffs	123
Guangzhou	117
Toronto	116
Santa Clara	109
São Paulo	101
Munich	95
London	89
Düsseldorf	83
Tokyo	76
Verona	71
Chennai	70
Mexico City	69
Warsaw	68
Hefei	64
Shanghai	54
Frankfurt am Main	51
Manchester	49
Nanjing	49
Kunming	48
Brussels	45
Brooklyn	43
Abuja	42
Norwalk	42
Hangzhou	40
Amsterdam	39
Buffalo	38
Jinan	38
Turku	36
Denver	35
Montreal	35
Pune	34
Da Nang	33
Boston	32
Stockholm	32
Johannesburg	31
Phoenix	31
Shenzhen	31
Washington	30
Haiphong	29
Kocaeli	29
Fuzhou	28
Mumbai	26
Tianjin	26
Poplar	25
San Francisco	23
Atlanta	22
Redwood City	20
Wuhan	20
Zhengzhou	19
Belo Horizonte	18
Falls Church	18
Nuremberg	18
St Petersburg	18
Changsha	17
Rio de Janeiro	17
Columbus	16
Sydney	16
Nanchang	15
Querétaro	15
Auburn Hills	14
Berlin	14
Curitiba	14
Edinburgh	14
Totale	35.793

Salva come PNG Salva come JPEG

Nome	#
CIITA-driven MHC class ii expressing tumor cells can efficiently prime naive CD4+ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells	265
Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response	258
Analysis of the structural heterogeneity and polymorphism of human Ia antigens. Four distinct subsets of molecules are coexpressed in the Ia pool of both DR1,1 homozygous and DR3,W6 heterozygous B cell lines	245
Boosting the MHC class II-restricted tumor antigen presentation to CD4+ T helper cells: A critical issue for triggering protective immunity and re-orienting the tumor microenvironment toward an anti-tumor state	244
Unsung hero Robert C. Gallo	236
Cytoplasmic Localization of HTLV-1 HBZ Protein: A Biomarker of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)	236
Translation and assembly of HLA-DR antigens in Xenopus oocytes injected with mRNA from a human B-cell line	233
Investigating Human T Cell Lymphotropic Retrovirus (HTLV) tax function with molecular and immunophenotypic techniques	231
Antibody-mediated activation of a deletion-mutant b-galactosidase defective in the a-region	230
Isolation of cDNA clones for the p33 invariant chain associated with HLA-DR antigens	228
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4(+) T lymphocytes for immunotherapy	225
Functional significance of polymorphism among MHC class II gene promoters	225
Reactivation by a trans-acting factor of human major histocompatibility complex Ia gene expression in interspecies hybrids between an Ia-negative human B-cell variant and an Ia-positive mouse B-cell lymphoma	224
Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response	222
Demonstration at the single cell level of the existence of distinct clusters of epitopes in two predefined human Ia molecular subsets	220
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells	217
An enhancer factor defect in a mutant Burkitt lymphoma cell line	216
Adequate Antigen Availability: A Key Issue for Novel Approaches to Tumor Vaccination and Tumor Immunotherapy	215
CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches	214
Active suppression of major histocompatibility complex class II gene expression during differentiation from B cells to plasma cells.	212
Cell lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression.	212
HTLV-1 HBZ Protein Resides Exclusively in the Cytoplasm of Infected Cells in Asymptomatic Carriers and HAM/TSP Patients	210
Human adipose-derived stem cells promote vascularization of collagen-based scaffolds transplanted into nude mice	209
Typing of a polymorphic human gene conferring susceptibility to insulin-dependent diabetes mellitus by picosecond-resolved FRET on non-purified/non-amplified genomic DNA	208
Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1	208
aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression.	207
Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL	207
A girl with Diabetes and severe Combined Immunodeficiency from Adenosine Deaminase Deficiency	207
Distinct HLA-DR epitopes and distinct families of HLA-Dr molecules defined by 15 monoclonal antibodies (mAb) either anti-DR or allo-anti-Iak cross-reacting with human DR molecule. I. Cross-inhibition studies of mAb cell surface fixation and differential binding of mAb to detergent-solubilized HLA molecules immobilized to a solid phase by a first mAb	206
Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy	205
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory.	205
The MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation	204
Transcriptional regulation of MHC class II genes	204
Host defense mechanisms against pathogens	203
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory	202
Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human	202
H2-RESTRICTED RECOGNITION OF CLONED HLA CLASS-I GENE-PRODUCTS EXPRESSED IN MOUSE CELLS	202
Detection of human chromosomes in somatic cell hybrids by PCR analysis	201
Antibody-mediated activation of genetically defective Escherichia coli beta-galactosidases by monoclonal antibodies produced by somatic cell hybrids	200
In vivo modification of major histocompatibility complex class II DRA promoter occupancy mediated by the AIR-1 trans-activator	200
Double-stranded deoxyribonucleic acid binds to HLA class II molecules and inhibits HLA class II-mediated antigen presentation	200
The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells	200
Allogeneic mixed lymphocyte reactions in humans : Pretreatment of either the stimulator or the responder cell population with monoclonal anti-Ia antibodies leads to an inhibition of cell proliferation	199
Sandwich enzyme immunoassay using three monoclonal antibodies against different epitopes of carcinoembryonic antigen "CEA".	199
APC gene mutations and allelic losses in sporadic ampullary tumours: evidence of genetic difference from tumours associated with familial adenomatous polyposis	199
Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells	197
The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators	196
Ia-negative B-cell variants reveal a coordinate regulation in the transcription of the HLA class II gene family	196
The MHC Class II transactivator CIITA inhibits the persistent activation of NF-kB by Tax-1	196
Biochemical aspects of human Ia molecules	194
Picosecond-resolved FRET on non-amplified DNA for identifying individuals genetically susceptible to type-1 diabetes	193
The MHC class II transactivator: prey and hunter in infectious diseases	191
Analisi dell’espressione genica in cellule epiteliali umane trattate con la proteina Tat di HIV	191
Binding of one monoclonal antibody to human Ia molecules can be enhanced by a second monoclonal antibody	188
Monoclonal antibodies against carcinoembryonic antigen (CEA) used in solid-phase enzyme immunoassay	188
The importance of cross-reactions between species: mouse allo-anti-Ia monoclonal antibodies as a powerful tool to define human Ia subsets	188
Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL	188
Autoimmunità e Malattie Autoimmuni	188
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.	187
Distinct forms of both a and b subunits are present in the human Ia molecular pool	186
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory	186
IL-2 mediated T cell proliferation in humans is blocked by a monoclonal antibody directed against monomorphic determinants of HLA-DR antigens.	185
SUSCEPTIBILITY OF HUMAN-MOUSE T-CELL HYBRIDS TO HIV-PRODUCTIVE INFECTION	185
Subsets of human Ia-like molecules defined by monoclonal antibodies	183
Analysis of the antigen specific T cell repertoire in HIV infection	183
Somatic cell hybrids producing antibodies specific to human fibronectin.	182
Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication	182
Evidence for a trans-acting activator function regulating the expression of the human CD5 antigen	182
Reducing the global burden of HTLV-1 infection: An agenda for research and action	182
Adequate Antigen Availability (AAA) in antitumor immunity: Definition and consequences for novel strategies of tumor prevention and antitumor treatment	181
Stable integration of mouse DNA into Ia-negative human B-lymphoma cells causes reexpression of the human Ia-positive phenotype.	180
Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines.	179
Expression of HLA-DR antigen in human class II mutant B-cell lines by double infection with retrovirus vectors.	179
A family of trans-acting factors with distinct regulatory functions control expression of MHC class II genes.	179
New strategies of mammary cancer vaccination	179
Enterovirus infection and low Treg function: two possible biomarkers of progression to autoimmune T1D.	179
CIITA-driven MHC class II expressing tumor cells as antigen presenting cell performers: Toward the construction of an optimal anti-tumor vaccine	179
Superinfection by Epstein-Barr virus of a subset of Raji cells is independent of HLA class-II antigens	177
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication	176
Assessment of the DQB1-DQA1 complete genotype allows best prediction for IDDM	176
The MHC class II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation.	176
Tumor Immunology meets Immunology: Modified cancer cells as professional APC for priming naÃ¯ve tumor-specific CD4+ T cells	175
The MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation	174
ras-Family gene mutations in neoplasia of the ampulla of Vater	173
Structural analysis of the CD69 early activation antigen by two monoclonal antibodies directed to different epitopes.	172
Insight into the molecular mechanism of CIITA-mediated inhibition of HIV-1 and HTLV transactivators	172
Tripartite motif 22 and class II transactivator restriction factors: Unveiling their concerted action against retroviruses	172
Interspecies somatic T cell hybrids as biological tools for studying gene expression during T cell development	171
THE HUMAN IA-ASSOCIATED INVARIANT CHAIN IS SYNTHESIZED IN IA-NEGATIVE B-CELL VARIANTS AND IS NOT EXPRESSED ON THE CELL-SURFACE OF BOTH IA-NEGATIVE AND IA-POSITIVE PARENTAL CELLS	170
A dual defensive role of CIITA against retroviral infections	169
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic virus type 1.	169
Neonatal Fc receptor is involved in the protection of fibrinogen after its intake in peripheral blood mononuclear cells	169
MHC: Orchestrating the immune response	168
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.	167
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma	167
Idiotype-specific neonatal suppression of phosphorylcholine-responsive B cells.	166
Different staphylococcal enterotoxins bind preferentially to distinct major histocompatibility complex class II isotypes	164
Treg function as a marker to define the susceptibility to T1DM clinical onset in a healthy subject with antibodies positivity?	164
New approaches of cancer vaccination and cancer immunotherapy based on the optimal stimulation of tumor-specific, MHC class II-restricted CD4+ T helper cells	164
Trans-acting element(s) operating across species barriers positively regulate expression of major histocompatibility complex class II genes.	163
Totale	19.561

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	186.708
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	186.708

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	1.577	0	0	0	0	0	0	0	0	0	232	462	883
2021/2022	3.229	392	414	271	231	114	95	124	219	150	468	278	473
2022/2023	4.358	470	150	270	468	343	947	6	640	633	135	167	129
2023/2024	8.694	1.434	1.405	1.535	1.536	1.645	542	64	110	272	44	18	89
2024/2025	4.898	53	74	928	149	222	235	218	321	563	300	402	1.433
2025/2026	10.720	763	658	542	1.610	1.087	799	2.785	742	1.262	472	0	0
Totale													51.409